Stanozolol in chronic urticaria: a double blind, placebo controlled trial

J Dermatol. 2001 Jun;28(6):299-302. doi: 10.1111/j.1346-8138.2001.tb00137.x.


H1-type antihistamine drugs are mainstays in the management of chronic urticaria. For patients with refractory, chronic, idiopathic urticaria who have failed to benefit from conventional therapy, other safe therapeutic modalities are required. To evaluate the role of stanozolol as an adjunctive therapeutic agent with H1-antihistamine in refractory chronic idiopathic urticaria, we conducted this study. Fifty-eight patients with chronic refractory urticaria were enrolled in this trial and were randomly assigned to two groups (A and B). Patients in group A received 2 mg stanozolol twice daily along with cetrizine 10 mg daily. Patients in group B received cetrizine 10 mg daily and placebo tablets twice daily. The improvement was monitored by estimation of severity score. Of the 58 patients, 26 in group A and 24 in group B could be evaluated. At the end of 12 weeks, 17 patients in group A showed marked to complete resolution as compared to 7 patients in group B (chi-square p<0.01). The intention to treat analysis p value was a found to be <0.007. There was a highly significant decrease in mean severity score at 12 weeks (p<0.001) in group A patients. The present study demonstrated that stanozolol is an effective and safe adjuvant therapy for treatment of chronic refractory urticaria.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Anabolic Agents / therapeutic use*
  • Cetirizine / therapeutic use
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Histamine H1 Antagonists / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Stanozolol / therapeutic use*
  • Treatment Outcome
  • Urticaria / drug therapy*
  • Urticaria / pathology


  • Anabolic Agents
  • Histamine H1 Antagonists
  • Stanozolol
  • Cetirizine